Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Asset Writedowns and Impairment: 2024-2025

Historic Asset Writedowns and Impairment for Phathom Pharmaceuticals (PHAT) over the last 1 years, with Jun 2025 value amounting to -$80,000.

  • Phathom Pharmaceuticals' Asset Writedowns and Impairment fell 132.92% to -$80,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $1.4 million, marking a year-over-year change of. This contributed to the annual value of $836,000 for FY2024, which is N/A change from last year.
  • As of Q2 2025, Phathom Pharmaceuticals' Asset Writedowns and Impairment stood at -$80,000, which was down 108.90% from $899,000 recorded in Q1 2025.
  • Over the past 5 years, Phathom Pharmaceuticals' Asset Writedowns and Impairment peaked at $899,000 during Q1 2025, and registered a low of -$80,000 during Q2 2025.
  • In the last 2 years, Phathom Pharmaceuticals' Asset Writedowns and Impairment had a median value of $243,000 in 2024 and averaged $331,000.
  • Data for Phathom Pharmaceuticals' Asset Writedowns and Impairment shows a maximum YoY slumped of 132.92% (in 2025) over the last 5 years.
  • Over the past 2 years, Phathom Pharmaceuticals' Asset Writedowns and Impairment (Quarterly) stood at $120,000 in 2024, then crashed by 132.92% to -$80,000 in 2025.
  • Its Asset Writedowns and Impairment stands at -$80,000 for Q2 2025, versus $899,000 for Q1 2025 and $120,000 for Q4 2024.